GlassScriptPhysician profile
Phone M Win
NPI 1194702100
$16,578.88
in general payments reported to CMS, 2019-2025
25 companies · $21.34 in 2025
The $21.34 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,065 · 2020: $1,476 · 2021: $2,128 · 2022: $3,188 · 2023: $4,377 · 2024: $2,322 · 2025: $21.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,622 · Education: $99.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,622.23 |
| Education | $99.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $3,376.84 | 2019-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $2,544.27 | 2019-2024 | Austedo Xr, Austedo, Uzedy |
| Abbvie INC. | $2,536.52 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $1,695.34 | 2019-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Neurocrine Biosciences, INC. | $1,251.25 | 2019-2024 | Ingrezza |
| Alkermes, INC. | $1,215.16 | 2019-2024 | Lybalvi, Aristada |
| Sunovion Pharmaceuticals INC. | $824.99 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $811.99 | 2020-2024 | Caplyta |
| Axsome Therapeutics, INC. | $673.87 | 2023-2024 | Auvelity, Sunosi |
| Allergan, INC. | $558.82 | 2019-2020 | |
| Orexo US, INC. | $207.19 | 2019-2024 | Zubsolv |
| Corium, LLC | $195.70 | 2023 | Azstarys |
| Indivior INC. | $135.95 | 2022-2024 | Sublocade |
| Eisai INC. | $87.63 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $86.20 | 2022-2023 | Qelbree |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $69.39 | 2023-2024 | Trintellix |
| Braeburn INC. | $68.89 | 2024 | Brixadi |
| Jazz Pharmaceuticals INC. | $54.12 | 2021 | |
| Neuronetics, INC. | $50.73 | 2024 | Neurostar Tms Therapy System |
| Biogen, INC. | $49.89 | 2024 | |
| Alnylam Pharmaceuticals INC. | $26.99 | 2023 | Onpattro |
| Ironshore Pharmaceuticals INC. | $17.38 | 2024 | |
| Idorsia Pharmaceuticals US INC | $15.91 | 2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $13.00 | 2019 | |
| Mdd US Operations, LLC | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phone Win listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.